GeneDx Holdings Corp. (NASDAQ:WGS) Shares Sold by Deutsche Bank AG

Deutsche Bank AG lowered its stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 91.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,375 shares of the company's stock after selling 113,731 shares during the quarter. Deutsche Bank AG's holdings in GeneDx were worth $797,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Sterling Capital Management LLC raised its position in shares of GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after buying an additional 316 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of GeneDx during the 4th quarter valued at about $28,000. Comerica Bank purchased a new stake in shares of GeneDx during the 4th quarter valued at about $50,000. Quarry LP purchased a new stake in shares of GeneDx during the 4th quarter valued at about $78,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of GeneDx during the 4th quarter valued at about $200,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

GeneDx Trading Up 1.0%

WGS stock traded up $0.73 during mid-day trading on Friday, reaching $70.71. The company had a trading volume of 626,360 shares, compared to its average volume of 772,034. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market capitalization of $2.02 billion, a PE ratio of -36.08 and a beta of 1.96. The firm has a 50 day moving average of $81.79 and a 200 day moving average of $82.22. GeneDx Holdings Corp. has a 12 month low of $20.01 and a 12 month high of $117.75.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.17. The business had revenue of $87.12 million for the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, equities analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Kevin Feeley sold 388 shares of the stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $113.09, for a total transaction of $43,878.92. Following the transaction, the chief financial officer now directly owns 3,337 shares in the company, valued at approximately $377,381.33. This trade represents a 10.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Keith A. Meister acquired 100,000 shares of the company's stock in a transaction dated Thursday, May 8th. The shares were acquired at an average price of $56.01 per share, for a total transaction of $5,601,000.00. Following the completion of the purchase, the director now owns 3,008,629 shares of the company's stock, valued at approximately $168,513,310.29. This represents a 3.44% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 139,390 shares of company stock worth $13,043,288 in the last three months. Corporate insiders own 29.60% of the company's stock.

Wall Street Analyst Weigh In

WGS has been the topic of several recent research reports. Wells Fargo & Company decreased their target price on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 1st. The Goldman Sachs Group increased their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. TD Securities reduced their price objective on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective on the stock in a research report on Friday, May 9th. Finally, Guggenheim initiated coverage on shares of GeneDx in a research report on Thursday, May 15th. They issued a "buy" rating and a $88.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $86.75.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.